Drugs / PA5108 Ocular Implant
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06964191 | May 2025 → Nov 2026 expected | ocular hypertension, open-angle glaucoma | PolyActiva Pty Ltd | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2023-11-02 | PolyActiva Pty Ltd | Results PolyActiva reports promising Phase 2a clinical trial results polyactiva.com ↗
The interim Phase 2a results demonstrate a sustained >20% reduction of Intraocular Pressure after 6 months with a favorable safety profile; 8 (out of 17 subjects) successfully dosed with a second implant. |
| 2022-03-17 | PolyActiva Pty Ltd | Results Positive Phase IIa results in glaucoma trial with low dose cohort polyactiva.com ↗ |
| 2022-03-17 | PolyActiva Pty Ltd | Results PolyActiva presents positive clinical trial results polyactiva.com ↗
The open-label, multicenter, Phase IIa study met both its primary and secondary efficacy endpoints of at least 20% IOP lowering in its low dose cohort |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-11-02 | PolyActiva Pty Ltd | PolyActiva reports promising Phase 2a clinical trial results polyactiva.com ↗ |
| 2022-03-17 | PolyActiva Pty Ltd | Positive Phase IIa results in glaucoma trial with low dose cohort polyactiva.com ↗ |
| 2022-03-17 | PolyActiva Pty Ltd | PolyActiva presents positive clinical trial results polyactiva.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PA5108 Ocular Implant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06964191 ↗ |
| Route | Other | “Intracameral PA5108 Ocular Implants” NCT06964191 ↗ |